Life Sciences Ontario (LSO) welcomes Budget 2025: Building Canada Strong and the federal government’s continued investment in innovation, research, and the life sciences sector
Ontario’s life sciences sector contributes $58.1 billion to Ontario’s GDP, generates $8.8 billion in government revenue,...
Life Sciences Ontario releases plan for Ontario to adjust health system to better deal with chronic diseases, starting with diabetes
Millions of Ontarians live with one or more chronic diseases, but the health system was designed 60 years ago mainly for acute illnesses
The plan outlines immediate steps to help diabetes care that could then be applied to other chronic diseases, so all are treated more efficiently
TORONTO, March 25, 2025 – Life Sciences Ontario (LSO) today released a vision paper outlining a concrete and viable path for Ontario to allow its health system to better diagnose, treat and improve the lives of the millions of residents who live with one or more chronic diseases.
Titled “Going Upstream: Toward an Ontario Chronic Disease Strategy, Starting with Diabetes,” this paper—developed in partnership with Diabetes Canada and the Health Charities Coalition of Canada (HCCC)—presents concrete, actionable steps to prevent, mitigate, and manage chronic diseases. It starts by addressing diabetes, which currently affects 1.7 million Ontarians, a number expected to grow to 2.3 million by 2034.
This initiative builds on Ontario’s Motion 45, identifying both immediate and long-term actions needed to develop a comprehensive chronic disease strategy, beginning with diabetes care.
This paper has been developed by Life Sciences Ontario in partnership with Diabetes Canada and Health Charities Coalition of Canada (HCCC) with financial support from Dexcom Canada, Co., Johnson & Johnson Canada, Novo Nordisk Canada Inc., Pfizer Canada ULC., Roche Canada, and Vertex Pharmaceuticals (Canada) Inc.
